APA (7th ed.) Citation

PA, M., N, F., N, D., PM, A., LE, D., A, K., . . . JA, L. (2024). Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 42(31), 3725. https://doi.org/10.1200/JCO.24.00020

Chicago Style (17th ed.) Citation

PA, Meyers, et al. "Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 42, no. 31 (2024): 3725. https://doi.org/10.1200/JCO.24.00020.

MLA (9th ed.) Citation

PA, Meyers, et al. "Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 42, no. 31, 2024, p. 3725, https://doi.org/10.1200/JCO.24.00020.